The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor
 
Tareq Abuasab
No Relationships to Disclose
 
Yesid Alvarado Valero
Research Funding - Astex Pharmaceuticals (Inst); BerGenBio (Inst); Daiichi Sankyo/Lilly (Inst); FibroGen (Inst); Jazz Pharmaceuticals (Inst); Sun Pharma (Inst)
 
Ghayas C. Issa
Consulting or Advisory Role - Kura Oncology; Novartis
Research Funding - Kura Oncology (Inst); Novartis (Inst); Syndax (Inst)
 
Rabiul Islam
No Relationships to Disclose
 
Nicholas James Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
Musa Yilmaz
Research Funding - Daiichi Sankyo; Pfizer; Pfizer
 
Nitin Jain
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Adaptive Biotechnologies; ADC Therapeutics; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; Pfizer; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cellectis (Inst); CRC Oncology (Inst); Dialectic Therapeutics (Inst); fate therapeutics (Inst); Genentech/Roche (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Medisix Therapeutics (Inst); MingSight (Inst); NovalGen (Inst); Pfizer (Inst); Pharmacyclics (Inst); Precision Biosciences (Inst); Seagen (Inst); SERVIER (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - CRLF2 Bispecific antibody
 
Lucia Masarova
No Relationships to Disclose
 
Steven Mitchell Kornblau
No Relationships to Disclose
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda
 
Naveen Pemmaraju
Employment - MD Anderson Cancer Center
Leadership - ASCO; ASH
Honoraria - Abbvie; Aptitude Health; Blueprint Medicines; CareDX; Celgene; DAVA Pharmaceuticals; Incyte; LFB Biotechnologies; MustangBio; NeoPharm; Novartis; Roche Molecular Diagnostics; Springer; Stemline Therapeutics
Consulting or Advisory Role - Astellas Pharma; Blueprint Medicines; Bristol Myers Squibb; Clearview Healthcare Partners; CTI BioPharma Corp; Immunogen; Pacylex; Protagonist Therapeutics; Triptych Health Partners
Research Funding - Abbvie; Affymetrix/Thermo Fisher Scientific; Cellectis; Daiichi Sankyo; MustangBio; Novartis; Plexxikon; Samus Therapeutics; Stemline Therapeutics
Travel, Accommodations, Expenses - Abbvie; Celgene; DAVA Oncology; MustangBio; Stemline Therapeutics
(OPTIONAL) Uncompensated Relationships - Dan's House of Hope; Oncology Times
 
Guillermo Montalban Bravo
Research Funding - IFM Therapeutics (Inst)
 
Sherry Pierce
No Relationships to Disclose
 
Courtney Denton Dinardo
Leadership - Notable Labs
Stock and Other Ownership Interests - Notable Labs
Honoraria - Abbvie; Agios; Bluebird Bio; Celgene; Foghorn Therapeutics; Genentech/Abbvie; Genmab; GlaxoSmithKline; Jazz Pharmaceuticals; Novartis; SERVIER; Takeda
Consulting or Advisory Role - Abbvie; Agios; Celgene; GlaxoSmithKline
Research Funding - Abbvie; AGIOS; Celgene; Cleave Therapeutics; Daiichi Sankyo; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals
 
Tapan M. Kadia
Honoraria - CURE
Consulting or Advisory Role - Abbvie/Genentech; Agios; Daiichi Sankyo/UCB Japan; Jazz Pharmaceuticals; Liberum; Novartis; Pfizer; Pinot Bio; Sanofi; SERVIER
Research Funding - Amgen; Ascentage Pharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; BiolineRx; Bristol-Myers Squibb; Celgene; cellenkos; Cyclacel; Delta-Fly Pharma; Genentech/Abbvie; Genfleet Therapeutics; Glycomimetics; Incyte; Iterion Therapeutics; Jazz Pharmaceuticals; Pfizer; Pulmotech
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Novartis; Pfizer; SERVIER; Shattuck Labs; Syndax; Trillium Therapeutics
Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead Sciences; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium Therapeutics; Trovagene
 
Marina Konopleva
Honoraria - Abbvie; Amgen; Amgen; Forty Seven; Genentech; KisoJi Biotechnology; Roche; Stemline Therapeutics
Consulting or Advisory Role - AbbVie; Amgen; Forty Seven; Genentech/Roche; Janssen; KisoJi Biotechnology; KisoJi Biotechnology; Roche; Stemline Therapeutics
Research Funding - Abbvie (Inst); Ablynx (Inst); Agios (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Forty Seven (Inst); Genentech (Inst); Lilly (Inst); Roche (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Eli LIlly- Research Funding; Issued/ Licensed; Novartis- PENDING; Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities); Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities)
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis